IMBiotechnologies
IMBiotechnologies is a privately held Edmonton-based medical device company that commercializes Ekobi Embolization Microspheres, a first-in-class biodegradable PLGA embolic agent detectable by ultrasound, sold through US GPOs to office-based lab and ambulatory surgical center clinics for embolotherapy procedures.
- Company typePrivate
- Founded2008
- HeadquartersEdmonton, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What IMBiotechnologies does
IMBiotechnologies Ltd. is a privately held Canadian medical device company incorporated in Alberta in 2008 and headquartered in Edmonton, focused on commercializing products in embolotherapy. The company's lead product is Ekobi Embolization Microspheres, a first-in-class biodegradable embolic agent detectable by ultrasound. The microspheres are made from poly(lactic-co-glycolic acid) (PLGA), an established polymer used in approved medical devices and drug products, and are delivered via catheter to selectively block blood supply to target tissue. Ekobi degrades and is completely eliminated from the body in 4-6 months as carbon dioxide and water, distinguishing it from permanent embolic implants. The product line is offered in five calibrated size variants (Ekobi 502 through 505) covering 40-800 µm to match different vascular targets, and the only embolic that uses platelet binding to create a natural clot.
The company sells Ekobi as a prescription medical device under quote-based pricing, distributing primarily through US group purchasing organizations (Embol Experts and Medicus Management) that serve office-based laboratory and ambulatory surgical center clinics, with direct ordering via email. Approved indications include treatment of unresectable/inoperable hypervascularized tumors (FDA 510(k) and Health Canada Class IV), benign prostatic hyperplasia (Health Canada 2018), and uterine fibroids (Health Canada 2019), with additional clearances in Israel and Iran. End-markets are interventional radiologists and the OBL/ASC channel performing procedures for liver/kidney cancer, fibroids, BPH, and increasingly osteoarthritic knee pain (genicular artery embolization) under development.
IMB operates with 1-10 employees, is pursuing a reverse takeover of Contagious Gaming Inc. to list on the Canadian Securities Exchange, and has signed a February 2025 master service agreement with LamaMed Solutions Inc. for contract manufacturing to scale supply. Recent go-to-market moves include supply agreements with two US-focused GPOs (Embol Experts in February 2024 and Medicus Management in June 2024) and engagement of Dr. Osman Ahmed (University of Chicago) as Clinical Advisor in February 2025 to support expanded commercialization.
IMBiotechnologies firmographics
Firmographics- Name
- IMBiotechnologies
- Legal name
- IMBIOTECHNOLOGIES LTD.
- Website
- https://imbiotechnologies.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- IMBiotechnologies is a privately held Edmonton-based medical device company that commercializes Ekobi Embolization Microspheres, a first-in-class biodegradable PLGA embolic agent detectable by ultrasound, sold through US GPOs to office-based lab and ambulatory surgical center clinics for embolotherapy procedures.
- Ownership category
- akta.pro rank
Where IMBiotechnologies is headquartered
LocationHeadquarters
- HQ city
- Edmonton
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
IMBiotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of Ekobi Embolization Microspheres, a prescription medical device. Products are sold in Canada and USA through GPOs and direct ordering. The device is available in calibrated sizes for different embolization applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription medical device - pricing not publicly available |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
IMBiotechnologies product offering
Product offeringCore offering
IMBiotechnologies develops and commercializes Ekobi Embolization Microspheres, a prescription medical device used in embolotherapy procedures. The microspheres are made from poly(lactic-co-glycolic acid) (PLGA) and are designed to be delivered via catheter to selectively block blood flow to target tissues such as hypervascularized tumors, uterine fibroids, and enlarged prostates (BPH). The product is available in five calibrated size variants ranging from 40 µm to 800 µm.
Product overview
IMBiotechnologies is a single-product medical device company focused on embolotherapy. The core offering is the Ekobi® Embolization Microspheres platform - a first-in-class biodegradable embolic agent detectable by ultrasound. The product line consists of microspheres available in five calibrated size variants (Ekobi 502 through Ekobi 505) ranging from 40 µm to 800 µm, designed for different vascular applications. The technology is used in minimally invasive embolotherapy procedures to selectively block blood supply to target tissues, treating conditions including liver cancer (HCC), kidney cancer (RCC), uterine fibroids, and benign prostatic hyperplasia (BPH).
Differentiator
Problem solved
Functional benefit
Products and services
- Ekobi 502 Embolization Microspheres Biodegradable embolic agent with particle size of 75-150 µm for embolization of distal micro-vasculature; suitable for use with microcatheters. Sold as a prescription medical device to interventional radiologists and healthcare facilities.
- Ekobi 503P Embolization Microspheres Biodegradable embolic agent with particle size of 150-180 µm for embolization of arteries and arterioles 0.2mm to 2mm in diameter; suitable for use with 2.4F microcatheters or larger. Sold as a prescription medical device to interventional radiologists and healthcare facilities.
- Ekobi 503L Embolization Microspheres Biodegradable embolic agent with particle size of 180-212 µm for embolization of arteries and arterioles 0.2mm to 2mm in diameter; suitable for use with 2.8F microcatheters or larger. Sold as a prescription medical device to interventional radiologists and healthcare facilities.
- Ekobi 504 Embolization Microspheres Biodegradable embolic agent with particle size of 212-300 µm for embolization of arteries and arterioles 0.4mm to 4mm; suitable for use with 4F catheters or larger. Sold as a prescription medical device to interventional radiologists and healthcare facilities.
- Ekobi 505 Embolization Microspheres Biodegradable embolic agent with particle size of 300-425 µm for embolization of arteries and arterioles 0.4mm to 4mm; suitable for use with 4F catheters or larger. Sold as a prescription medical device to interventional radiologists and healthcare facilities.
Quantifiable outcome
- UFE effectiveness rate of 71-92% with >90% patient satisfaction
- +2 more outcomes
Companies that use IMBiotechnologies
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
IMBiotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
IMBiotechnologies partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- LamaMed Solutions Inc.coreMaster service agreement with LamaMed Solutions Inc. for manufacturing of Ekobi Embolization Microspheres product for commercial sale. LamaMed is a privately held, San Francisco Bay area based med-tech innovator specializing in design, development and rapid manufacturing scale up of catheter systems, mechanical devices, and resorbable implants. The partnership enables IMB to meet growing demand driven by rising market adoption.
- Dr. Osman AhmedminorDr. Osman Ahmed joined as Clinical Advisor to provide guidance supporting development and expanded commercialization of Ekobi Embolization Microspheres. Dr. Ahmed is an internationally respected thought leader in minimally invasive embolization procedures at University of Chicago Medicine.
- Medicus Management, LLCcoreSupply agreement with Medicus Management, LLC, a group purchasing organization (GPO) supplying twenty OBL and ASC clinics focused on minimally-invasive procedures. Medicus Management is a full-service business intelligence partner for vascular outpatient practices, founded by a physician for physicians.
- Embol Experts, LLCcoreSupply agreement with Embol Experts, LLC, one of the largest GPOs in the US supplying office-based laboratory (OBL) and ambulatory surgical center (ASC) clinics focused on minimally-invasive procedures. Embol Experts is a joint venture between Arthritis Knee Pain Centers and Embolix.
- Alberta InnovatesminorAlberta Innovates provided funding and support for clinical studies. The clinical study in patients with BPH was conducted at the University of Alberta and was supported, in part, by funding from Alberta Innovates.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
IMBiotechnologies competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Largest player in the embolic microsphere market through Contour PVA and Embozene. Overlaps with IMB across all of Ekobi's indications (hypervascularized tumors, BPH, uterine fibroids) and offers a full interventional radiology and oncology portfolio — but as part of a much broader device portfolio rather than as an embolic specialist.
- AngioDynamics: Interventional oncology and vascular access company offering embolization products and catheter-delivered therapies. Overlaps with IMB in tumor embolization and broader catheter-delivered therapy markets, with much deeper commercialization capability than a 1-10 person team.
- Guerbet: Imaging and interventional solutions company offering contrast media and certain embolization products. Adjacent but relevant peer operating in the same interventional radiology purchasing environment where IMB's Ekobi is sold.
- Cook Medical: Large private medical device company with broad embolization portfolio including coils and particles. Established direct sales force and clinical evidence infrastructure that compete for interventional radiologist mindshare against IMB's offering.
Direct peers
- Sirtex Medical: Focused on radioembolization (SIR-Spheres) and related embolic technologies for liver cancer and other tumors. Direct peer in interventional oncology embolic delivery with similar physician channels and clinical-evidence strategy as IMB's Ekobi platform.
- Penumbra: Public interventional therapy company with significant presence in vascular embolization and oncology. Comparable end-customers (interventional radiologists) and overlapping therapeutic areas and procedural channels, but broader portfolio and substantially deeper commercial resources.
- Terumo Medical: Provides embolic microspheres and related interventional radiology devices used in tumor embolization and UFE. Direct peer with overlapping embolic product portfolio and the same interventional radiologist customer base as IMB.
- Merit Medical Systems: Maker of Embosphere Microspheres, one of the most clinically established and widely used spherical embolic agents in tumor and UFE applications. Direct competitor to Ekobi with comparable calibrated-size offerings and shared interventional radiology customer base.
Emerging players
- ABK Biomedical: Pre-commercial/early commercial medical device company developing next-generation embolic microspheres for hypervascular tumors and other embolotherapy indications. Closely comparable in stage, indication focus, and technical differentiation approach to IMB.
- Embolix: Early-stage company in the interventional embolization space and a joint-venture partner behind Embol Experts GPO (one of IMB's two US distribution partners). Comparable in size, indication focus, and clinical positioning to IMB, and unusually close on go-to-market overlap.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
IMBiotechnologies social profiles
Digital presenceIMBiotechnologies compliance and trust
Trust signalCompliance2 records
IMBiotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
IMBiotechnologies leadership team
Management profileNumber of profiles
Profiles4 records
IMBiotechnologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IMBiotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IMBiotechnologies
What does IMBiotechnologies do?
IMBiotechnologies develops and commercializes Ekobi Embolization Microspheres, a prescription medical device used in embolotherapy procedures. The microspheres are made from poly(lactic-co-glycolic acid) (PLGA) and are designed to be delivered via catheter to selectively block blood flow to target tissues such as hypervascularized tumors, uterine fibroids, and enlarged prostates (BPH). The product is available in five calibrated size variants ranging from 40 µm to 800 µm.
Is IMBiotechnologies a public or private company?
IMBiotechnologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was IMBiotechnologies founded?
IMBiotechnologies was founded in 2008. It employs 1 to 10 people.
Where is IMBiotechnologies based?
IMBiotechnologies is headquartered in Edmonton, Canada, in the North America region.
How does IMBiotechnologies make money?
One revenue line is on record: medical Device Sales.
Who are IMBiotechnologies's main competitors?
Broad incumbents on record are Boston Scientific, AngioDynamics, Guerbet and Cook Medical. Direct peers are Sirtex Medical, Penumbra, Terumo Medical and Merit Medical Systems. Emerging players are ABK Biomedical and Embolix.
Does IMBiotechnologies have an API?
No public API is recorded for IMBiotechnologies.